HBOT Conversations:
Join us for interviews with researchers, practitioners, industry experts, and patients to share their stories, successes, and expertise relative to hyperbaric oxygen therapy
Subscribe. Join the discussion. Share the hope.
Listen to or Watch the HBOT Conversations Podcast
Listen to the HBOT Converstations podcast by downloading it from your favorite podcasting platform or scroll down and watch an episode here on the HBOT News website:
Watch the HBOT Conversations Podcast
Subscribe Now, It’s Free !
Recent HBOT News
Extivita Proposes Minimize Loss of Life From COVID-19 with HBOT
Hyperbaric Oxygen Therapy (HBOT) can destroy harmful bacteria and viruses, while enhancing the body’s natural defenses. We propose HBOT for high risk, early stage COVID-19 patients, recommending this novel use of pressure and oxygen based on its low risk and...
Emergency Hyperbaric Oxygen for Respiratory Distress or Failure for COVID-19 Patients
April 2, 2020, Dr. David Lee posted a new clinical trial on the NIH Clinical Trials website to study the use of Hyperbaric Oxygen Therapy (HBOT) to treat COVID-10. The study is listed as "Not Recruiting Yet," but has an estimated completion date of July 2020. ...
Clinical Trial – Pseudoephedrine Prophylaxis for Prevention of Middle Ear Barotrauma in Hyperbaric Oxygen Therapy
Hyperbaric oxygen therapy (HBOT) utilizes 100% oxygen delivery at a pressure greater than 1 atm for the treatment of various emergent medical conditions including carbon monoxide poisoning. The most commonly associated complication of HBOT is middle ear barotrauma (MEB) which occurs when the eustachian tube does not allow air to enter the middle ear space to equalize the pressure between the ambient environment and the inner ear. Patients experiencing MEB usually feel pressure or pain in their ear(s). The spectrum of symptoms ranges from sensation of ear fullness and muffled hearing to severe pain, vertigo and tympanic membrane rupture. HBOT has not been studied. The investigators plan to perform a randomized double blind placebo control trial to determine if pseudoephedrine is effective in decreasing the rate of MEB during HBOT.